Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
- PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
- Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
- Japan to Boost Number of HPV Vaccination Base Hospitals
September 9, 2022
- What Is Seen as New Omicron Variant Detected in Japan: NIID
September 9, 2022
- LDP Group Urges Thorough Discussions on New Data for Shionogi COVID Pill Once Out
September 8, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
- Ultrasound Dementia Therapy Machine in Line for First Sakigake Device Designation, Japan Submission Eyed in 2025
September 6, 2022
- MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- Tatsumi Kagaku Faces Biz Improvement Order over Discrepant Manufacturing Method, Falsified Records
September 5, 2022
- METI Seeks 7 Billion Yen to Develop Next-Gen Drug Discovery Tech Platform: FY2023 Budget Request
September 5, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
September 5, 2022
- Japan to Supply AstraZeneca’s Evusheld Only for COVID-19 Prevention
September 2, 2022
- MHLW Council OKs Public Knowledge-Based Applications for FOLFOX Therapy for Stomach Cancer
September 2, 2022
- Experts Raise Alarm on Declining Attractiveness of Japan Market: New Panel
September 1, 2022
- New Expert Panel on Drug Distribution and Pricing Boots Up; 2-Step Proposals Eyed for Off-Year Revision, 2024 Reform
September 1, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…